Open AccessAcarbose improves glycemic control as add-on or monotherapy in Indian type-2 diabetes: Findings from the GlucoVIP multinational observational study
Author(s) -
Elizabeth Philip,
Meenakshi L Sundaram,
Rupam Das,
Sushil Kumar Chauhan,
Sandeep Deshpande,
Sanjay Ambhore,
Rahul Rathod,
Pravin Manjrekar
Publication year - 2013
Publication title -
indian journal of endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.456
H-Index - 28
eISSN - 2230-9500
pISSN - 2230-8210
DOI - 10.4103/2230-8210.123565
Subject(s) - medicine , acarbose , glycemic , tolerability , type 2 diabetes mellitus , observational study , diabetes mellitus , type 2 diabetes , waist , gastroenterology , insulin , endocrinology , body mass index , adverse effect
To investigate the efficacy and tolerability of the anti-diabetic agent acarbose (Glucobay(®)) as add-on or monotherapy in a range of patients with type-2 diabetes mellitus (T2DM), including those with cardiovascular morbidities in India.